Macular Features on Spectral-Domain Optical Coherence Tomography Imaging Associated With Visual Acuity in Coats’ Disease

Sally S. Ong, Prithvi Mruthunjaya, Sandra Stinnett, Lejla Vajzovic, and Cynthia A. Toth

1Department of Ophthalmology, Duke University Medical Center, Durham, North Carolina, United States
2Department of Ophthalmology, Stanford University Medical Center, Palo Alto, California, United States

Correspondence: Cynthia A. Toth, Department of Ophthalmology, Duke University Eye Center, 2351 Erwin Road, Durham, NC 27710, USA; cynthia.toth@duke.edu.
Submitted: February 14, 2018
Accepted: April 21, 2018
Citation: Ong SS, Mruthunjaya P, Stinnett S, Vajzovic L, Toth CA. Macular features on spectral-domain optical coherence tomography imaging associated with visual acuity in Coats’ disease. Invest Ophthalmol Vis Sci. 2018;59:3161-3174. https://doi.org/10.1167/iovs.18-24109

PURPOSE. To investigate the association between macular features on spectral-domain optical coherence tomography (SD-OCT) and visual acuity (VA) in Coats’ disease.

METHODS. Thirty-nine eyes (39 patients) with SD-OCT from January 1, 2008 to December 31, 2016 were reviewed for SD-OCT features. Central subfield (CSF) SD-OCT findings were analyzed relative to VA (logarithm of the minimum angle of resolution) at baseline and final visit (when follow-up > 6 months) and across visits.

RESULTS. Mean VA ± standard deviation at baseline (37 eyes) was 0.92 ± 0.82. SD-OCT features associated with worse VA included, for treatment-naïve eyes (n = 21), outer retinal atrophy (ORA) (1.18 ± 0.34 with versus 0.20 ± 0.30 without, P = 0.005), subretinal fluid (SRF) (1.80 ± 0.65 vs. 0.65 ± 0.50, P = 0.008), bright hyperreflectivities (1.23 ± 0.68 vs. 0.52 ± 0.53, P = 0.02), thicker foveal subretinal space (r² = 0.32, P = 0.01), and CSF (r² = 0.39, P = 0.007); and for previously treated eyes (n = 16), a compact hyperreflective structure (1.60 ± 0.88 vs. 0.56 ± 0.64, P = 0.02) and ORA (1.34 ± 0.86 vs. 0.30 ± 0.44, P = 0.01). At final follow-up (n = 22), mean VA was 0.81 ± 0.83. Eyes with final VA < 20/200 (n = 6, vs. >20/60, n = 11) more commonly had a compact hyperreflective structure and ORA at baseline and final visit (P < 0.05). Mean change in VA from baseline (n = 20) was −0.20 ± 0.59. Mean improvement in VA (range, −0.52 to −1.127) occurred in eyes with baseline SRF (P = 0.02) and bright hyperreflectivities (P = 0.03). Changes in thickness that correlated with change in VA included those for the foveal subretinal space (r² = 0.52, P < 0.001) and CSF (r² = 0.26, P = 0.045).

CONCLUSIONS. A compact hyperreflective structure (fibrosis) and ORA were associated with poor final VA while SRF, bright hyperreflectivities (exudation), and foveal subretinal thickness were associated with VA improvement post treatment.

Keywords: Coats’ disease, spectral-domain optical coherence tomography, SD-OCT, visual acuity, pediatric retina, pediatric retinal imaging

Coats’ disease is characterized by idiopathic retinal vascular telangiectasias accompanied by retinal exudation and, in advanced cases, exudative retinal detachments.1 Traditional methods of diagnosing Coats’ disease include direct visualization with indirect ophthalmoscopy and fluorescein angiography (FA). Indirect ophthalmoscopy classically shows yellow lipid-rich subretinal and intraretinal exudates associated with retinal vascular abnormalities.2,3 While FA can demonstrate hyperfluorescent telangiectasias with bulb-like outpouchings. More recently, wide-field imaging has also been utilized as it can aid in the early detection of peripheral vascular changes.4 Spectral-domain optical coherence tomography (SD-OCT), a relatively newer imaging modality, confers the additional advantage of in vivo cross-sectional imaging for quantification of the type and extent of macular involvement. However, to date, there have been limited reports of OCT findings in Coats’ disease that describe structural and visual response to therapy.5-12 Most studies have only reported on the presence of cross-sectional abnormal OCT findings including epiretinal membrane, intraretinal cystoid spaces, subretinal fluid (SRF), lipid exudation, retinal scar, subretinal hyperreflective nodule, and macular atrophy.5,8,10-12 Except for fibrotic nodule,10,11,13 these publications did not address the relationship between these OCT morphologies and visual acuity (VA). Thus, there remains a need for assessment of the relationships between these retinal and subretinal morphologies with VA, whether these change in response to therapy, and how baseline SD-OCT features relate to VA outcomes. In this study, we characterize the retinal and subretinal SD-OCT findings in a large series of patients with Coats’ disease and associate these findings with the VA at every corresponding visit. We also examine the association between baseline SD-OCT features and final VA outcomes.

METHODS
This was a retrospective cohort study of all patients diagnosed with Coats’ disease who had SD-OCT imaging of the retina at Duke University Eye Center between January 1, 2008 and December 31, 2016. Patients who received tabletop SD-OCT...
imaging as part of standard clinical care were included based on a retrospective chart review while records for those who received handheld SD-OCT imaging were retrospectively obtained from a prospective OCT imaging study. Both studies were designed in accordance with the tenets of the Declaration of Helsinki, approved by the Institutional Review Board (IRB) at Duke University, and were Health Insurance Portability and Accountability Act (HIPAA) compliant. For the prospective study, a parent of each participant provided informed consent for imaging and access to medical records and the SD-OCT images were selected from an existing database of research imaging of pediatric patients.

Subjects with a diagnosis code of exudative retinopathy (International Classification of Diseases, 9th revision, Code 362.12) were identified through a DEDUCE (Duke Enterprise Unified Content Explorer) search. Eyes that did not have Coats’ disease fulfilling clinical criteria of having idiopathic retinal telangiectasia associated with or without exudation and/or exudative retinal detachments, lacked SD-OCT imaging, had poor-quality SD-OCTs (due to media opacities, excessive eye movement or blinking), or had no documented VAs were excluded from the study.

Demographic information, VA, staging of Coats’ disease, treatment history (laser or cryotherapy ablation, intravitreal steroid or anti-vascular endothelial growth factor, or surgical treatment with subretinal fluid drainage, vitrectomy, or scleral buckling), and total number of imaging sessions were documented. The best-corrected VA, when available, was documented. VA was measured with Snellen, Early Treatment Diabetic Retinopathy Study, Allen, or HOTV charts and converted to the logarithm of the minimum angle of resolution (logMAR) for statistical analysis. Low VAs (count fingers, hand movements, light perception and no light perception) measured on logMAR or Snellen charts were assigned logMAR values as previously described. At our institution, children with Coats’ disease were co-managed between the pediatric retina and pediatric ophthalmology services to ensure that amblyopia therapy was initiated appropriately and in a timely manner. Affected eyes were divided based on clinical examination, fundus photographs, or fluorescein angiograms (FA) into five stages of disease as previously described. Some patients had SD-OCT imaging taken months to years after diagnosis. In those records were reviewed, 48 were found to have had SD-OCT imaging. Upon review of the SD-OCT images, nine patients were further excluded from the study: six patients (two eyes with stages 3A1 and 3A2 disease, one eye with stage 3B disease, and three eyes with extensive scarring) due to low-quality imaging, and an additional three patients who corresponding Heidelberg Spectralis platform. Quantitative data included (1) foveal sensory retinal thickness: internal limiting membrane (ILM) to outer border of the retina; (2) foveal total retinal thickness: ILM to Bruch’s membrane; (3) foveal subretinal thickness: outer border of the retina to Bruch’s membrane; (4) foveal choroidal thickness: Bruch’s membrane to choroidal–scleral junction; (5) central subfield (CSF) thickness: average thickness from ILM to Bruch’s membrane in a 1-mm-diameter circle centered on the fovea; and (6) total macular volume: from ILM to Bruch’s membrane in a 6-mm-diameter circle centered on the fovea. CSF scans were also evaluated for the presence or absence of SD-OCT features that included abnormalities of the vitreoretinal interface: vitreomacular adhesion or traction and epiretinal membrane (Figs. 1A, 1B); and within and beneath the retina: hyporeflective intraretinal cystoid spaces (which we did not describe as CME as these commonly had no FA leakage), bright hyperreflectivities that could be intra- or subretinal and corresponded to exudates on color photographs (Figs. 1C, 1D), SRF (Figs. 1E, 1F), a compact hyperreflective structure that corresponded to a fibrovascular nodule or macular fibrosis on color photographs (Figs. 1G, 1H), and outer retinal atrophy (ORA) subdivided by association with outer plexiform and outer nuclear layer loss, ellipsoid and interdigitation zone involvement and retinal pigment epithelial attenuation or atrophy (Figs. 1I, 1J). Since ORA could also be seen overlying a compact hyperreflective structure (Fig. 1H), ORA not overlying a compact hyperreflective structure was graded as a separate entity (Fig. 1J). Unless otherwise specified, ORA in this manuscript refers to ORA that can surround, but is not above a compact hyperreflective structure.

To better characterize SD-OCT findings of treatment naïve versus those who had prior treatment for Coats’ disease, we divided the population into these two groups for the analysis of SD-OCT features versus VA at baseline. Across all patient visits with both SD-OCT and VA available, we also compared the relationship between SD-OCT features with VA. Across the entire follow-up group (and then with subanalysis of eyes that were treatment naïve at baseline) we compared the baseline and final OCT features to good (better than 20/60) versus poor (worse than 20/200) VA outcomes at the final visit. We also compared baseline OCT features with change in VA from baseline to final visit in eyes with follow-up. For the longitudinal analysis, patients had to have follow-up of 6 months or longer.

Wilcoxon rank sum test was used to compare continuous variables between groups while the Fisher’s exact test was used to compare categorical variables between groups. The Wilcoxon signed rank test was used to compare paired data. Generalized estimating equations (GEEs) were used to analyze the relationship between SD-OCT features with VA for all imaging sessions for all eyes since data from all imaging sessions included multiple longitudinal observations from the same eyes. A P value of less than 0.05 was considered statistically significant. Statistical analysis was performed using SAS version 9.4 (SAS Institute, Inc., Cary, NC, USA) and JMP Pro version 13.0 (SAS Institute, Inc.).

RESULTS
A chart search revealed 84 patients with Coats’ disease and when those records were reviewed, 48 were found to have had SD-OCT imaging. Upon review of the SD-OCT images, nine patients were further excluded from the study: six patients (two eyes with stages 3A1 and 3A2 disease, one eye with stage 3B disease, and three eyes with extensive scarring) due to poor-quality imaging, and an additional three patients who...
FIGURE 1. Examples of graded features on spectral-domain optical coherence tomography (SD-OCT) and their corresponding color photographs. The dotted green lines on the left correspond to the SD-OCT sections on the right. All images were taken in treatment-naïve eyes. (A, B) Epiretinal membrane. (A) On color photography, epiretinal membrane is not easily visible but on (B) SD-OCT, epiretinal membrane appears as a hyperreflective membrane (white arrow) that can distort the foveal contour and cause retinal thickening. (C, D) Exudation. (C) On color photography, there is dense yellow exudation seen in the macula. (D) On SD-OCT, these exudates appear as bright hyperreflectivities intraretinally (white arrows) and subretinally (yellow arrow). SD-OCT also showed hyporeflective intraretinal cystoid spaces (red arrow) not otherwise visible on Macular SD-OCT Features and VA in Coats’ Disease.

IOVS | June 2018 | Vol. 59 | No. 7 | 3163
lacked VA data. This left 39 patients in the study, and 28 of these were children aged 18 or younger. One patient had bilateral involvement and the better eye was excluded from analysis. We had previously published a retrospective review comparing the visual outcomes for patients with Coats’ disease who sought treatment at our institution over two 10-year periods (1996–2005 and 2006–2015). Twenty-three eyes from 23 patients from the previously published cohort were included in this study.

Among the 39 eyes from 39 patients included in this study, 21 eyes were treatment naïve prior to their baseline SD-OCT while 18 eyes had received prior treatment. For the previously treated group, the average number of months (±standard deviation, SD) between the most recent prior treatment and the baseline OCT was 55.3 ± 58.8. Two eyes from the previously treated group did not have VA documented at the baseline visit but were included in the study since they had VA documented at the most recent follow-up. Baseline demographics, Coats’ disease staging,^15^ and clinical characteristics for the 39 eyes are listed in Table 1. For the 22 eyes that had follow-up VA and SD-OCT at ≥6 months, clinical characteristics are shown in Table 2. In total, there were 167 imaging sessions after exclusion of 11 imaging sessions due to uninterpretable images from extreme pathology and/or inability to fix (n = 7), lack of cooperation in young patients (n = 2), or data loss (n = 2). Of these 167 imaging sessions, 144 had documented VA at the time of the imaging session.

**Association of VA With SD-OCT Findings**

**VA at the Baseline Visit.** Mean VA ± SD at baseline (available for 37 eyes) was 0.92 ± 0.82 logMAR. In treatment-naive eyes at the baseline visit (n = 21), comparison of VA for patients with and without selected SD-OCT features in the CSF is shown in Table 3. CSF features that were associated with poorer baseline VA included any hyperreflective material (P = 0.001) that consisted of intraretinal bright hyperreflectivities (P = 0.02) and subretinal bright hyperreflectivities (P = 0.01) (Fig. 1D), SRF (P = 0.008) (Fig. 1F), and ORA (P = 0.005) (Fig. 1J). Note that all eyes with subretinal bright hyperreflectivities also had bright hyperreflectivities within the retina (Fig. 1D).

In addition, for the treatment-naïve group, the following SD-OCT findings were associated with worse VA: increasing foveal total retinal thickness (r² = 0.33, P = 0.01), CSF thickness (r² = 0.35, P = 0.007), and total macular volume (r² = 0.75, P < 0.0001). In contrast, foveal neurosensory retinal thickness (which did not include subretinal material and fluid, P = 0.55) and foveal choroidal thickness (P = 0.77) were not associated with VA. None of these retinal measurements were found to be associated with stage of disease (data not shown). Notably, this analysis excluded three of five eyes with a compact hyperreflective structure since the combination of a compact hyperreflective structure and neurosensory retinal extension beyond the axial frame of the OCT and thus quantitative measurements could not be obtained in these eyes.

For previously treated eyes at the baseline visit (n = 16), results for the comparison of VA with SD-OCT features at the same visit are shown in Table 3. Features associated with VA included the following: a compact hyperreflective structure (P = 0.02) (Fig. 1H) and ORA (P = 0.01) (Fig. 1J). None of the retinal thickness measurements (including those incorporating thicknesses of subretinal fluid and material) were found to be associated with VA (data not shown).

**VA at All Visits.** The comparison of VA with SD-OCT features at the same visit for all eyes at all available imaging sessions (n = 144) is shown in Table 4. Except for 24 visits, all visits were after at least one treatment session for Coats’ disease. A compact hyperreflective structure (P = 0.002) and ORA (P < 0.001) were associated with VA for this analysis. None of the retinal thickness measurements (including those incorporating thicknesses of subretinal fluid and material) were found to be associated with VA (data not shown).

**VA at the Most Recent Follow-Up.** For 22 eyes with follow-up ≥6 months, VA at the most recent visit was 0.81 ± 0.83 logMAR. Change in selected SD-OCT features from the baseline to final visits were as follows: No eyes with a compact hyperreflective structure (0/4) or ORA (0/9) had resolution of finding after treatment (Fig. 2) while all eyes with SRF (3/3) and subretinal bright hyperreflectivities (4/4), and a majority of eyes with intraretinal bright hyperreflectivities (6/8) had resolution of finding after treatment (Fig. 3). A few eyes that did not previously have a compact hyperreflective structure (2/18 eyes) and ORA (1/7 eyes) also newly developed these findings despite treatment. No eyes newly developed SRF or intraretinal or subretinal bright hyperreflectivities after treatment.

At the final visit for all 22 eyes with follow-up, certain SD-OCT features were more frequently found in eyes with final VA worse than 20/200 than in eyes with good final VA (better than 20/60) (Table 5). These included a compact hyperreflective structure (P = 0.006), ORA (P = 0.04), and hyporeflective intraretinal cystoid spaces (P = 0.03). Next, baseline SD-OCT features were analyzed relative to the final VA groups (Table 6). Some baseline features were more common in eyes with final VA worse than 20/200 in contrast to those with final VA better than 20/60. These included a compact hyperreflective structure (P = 0.05) and ORA (P = 0.02).

**Change in VA From Baseline to the Most Recent Visit.** Change in VA from baseline to the final follow-up was available for 20 eyes. The mean change in VA was −0.20 ± 0.59 logMAR. As shown in Table 7, a change in VA from baseline to the final follow-up was associated with baseline SRF (P = 0.02) and baseline intraretinal hyperreflectivities (P = 0.03) but not baseline subretinal bright hyperreflectivities (P = 0.09).

Given the improvement in VA associated with baseline SRF, we specifically examined two treatment-naïve eyes that had presented with stage 3A1 disease and two or three quadrants of foveal-involving SRF (Fig. 4). At presentation, both eyes also had exudates involving the fovea. Baseline VA was count fingers at 1 foot for both eyes. After treatment, SRF and exudation resolved for both eyes, but one eye developed extensive foveal fibrosis with overlying and adjacent ORA while the other developed extrfoveal fibrosis and ORA. At the most recent follow-up, the VAs for these eyes were 2/200 and 20/50, respectively.

We then compared the change in VA from baseline to the final visit with change in retinal thickness measurements (Fig. 5). Change in VA was correlated with change in foveal total retinal thickness (P = 0.02), foveal subretinal thickness (P <
### Table 1. Demographics and Baseline Ocular Characteristics

| Demographics, Characteristics, and Treatments | Treatment Naïve, $n = 21$ | Previously Treated, $n = 18$ | All, $n = 39$ |
|-----------------------------------------------|-----------------------------|-------------------------------|---------------|
| Age, y, mean ± SD (median, range)             | $12.7 \pm 9.2$ (10.3, 4.0–42.8) | $23.3 \pm 19.6$ (17.7, 3.8–75.7) | $17.2 \pm 15.4$ (13.2, 3.8–75.7) |
| Number of adults, age ≥ 18 y (%)              | 4 (19)                      | 7 (39)                       | 11 (28)       |
| Male sex, $n$ (%)                              | 18 (86)                     | 15 (83)                      | 33 (85)       |
| Right eye, $n$ (%)                             | 13 (62)                     | 11 (61)                      | 24 (62)       |
| VA at baseline, logMAR, mean ± SD (median, range)* | $0.86 \pm 0.70$ (0.90, 0.00–2.30) | $0.93 \pm 0.95$ (0.70, 0.00–2.90) | $0.92 \pm 0.82$ (0.90, 0.00–2.90) |
| Disease staging† prior to any treatment, $n$ (%) |                                      |                              |               |
| Stage 2A                                      | 3 (14)                      | 3 (17)                       | 6 (15)        |
| Stage 2B                                      | 9 (43)                      | 1 (6)                        | 10 (26)       |
| Stage 3A1                                     | 2 (10)                      | 2 (11)                       | 4 (10)        |
| Stage 3A2                                     | 0                           | 1 (6)                        | 1 (3)         |
| Stage 3B                                      | 0                           | 7 (39)                       | 7 (18)        |
| Unknown                                       | 0                           |                              |               |
| Treatment prior to baseline OCT, $n$ (%)       |                                      |                              |               |
| None                                          | 21 (100)                    | 0                            | 21 (54)       |
| Ablation only                                 | 0                           | 13 (72)                      | 13 (33)       |
| Ablation + anti-VEGF                          | 0                           | 3 (17)                       | 3 (8)         |
| Incisional surgery + anti-VEGF                | 0                           | 2 (11)                       | 2 (5)         |
| Time from first therapy session to baseline OCT, mo, mean ± SD (median, range) | -                           | $82.1 \pm 71.6$ (61.0, 11–254) | -             |
| Time from most recent treatment to baseline OCT, mo, mean ± SD (median, range) | -                           | $55.3 \pm 58.8$ (36.0, 1–182) | -             |

* VA at baseline available for 21 treatment-naïve eyes and 16 previously treated eyes (2 previously treated eyes did not have VA at baseline but had recorded VA at the final follow-up and were included in the study).

† Shields JA, Shields CL, Honavar SG, Demirci H, Cater J. Classification and management of Coats disease: the 2000 Proctor Lecture. *Am J Ophthalmol*. 2001;131:572–583.
| Visual Acuity, Staging, Treatments, and Follow-up | Treatment Naïve, \( n = 13 \) | Previously Treated, \( n = 9 \) | All, \( n = 22 \) |
|-----------------------------------------------|----------------|----------------|----------------|
| **Initial VA, logMAR, mean ± SD (median, range)** | \( 0.91 ± 0.74 (0.90, 0.00 to 2.30) \) | \( 0.99 ± 0.72 (0.70, 0.20 to 2.30) \) | \( 0.94 ± 0.72 (0.90, 0.00 to 2.30) \) |
| **Final VA, logMAR, mean ± SD (median, range)** | \( 0.57 ± 0.65 (0.40, 0.00 to 1.82) \) | \( 1.16 ± 0.97 (0.90, 0.10 to 2.90) \) | \( 0.81 ± 0.83 (0.45, 0.00 to 2.90) \) |
| **VA change from baseline to final follow-up, logMAR, mean ± SD (median, range)** | \( -0.54 ± 0.64 (-0.20, -2.00 to +0.52) \) | \( +0.07 ± 0.40 (0.00, -0.60 to +0.70) \) | \( -0.20 ± 0.59 (0.00, -2.00 to +0.70) \) |
| **Disease staging‡ prior to any treatment, \( n (\%) \)** | | | |
| Stage 2A | 3 (23) | 1 (11) | 4 (18) |
| Stage 2B | 6 (46) | 1 (11) | 7 (32) |
| Stage 3A1 | 2 (15) | 3 (33) | 5 (23) |
| Stage 3A2 | 2 (15) | 2 (22) | 4 (18) |
| Stage 3B | 0 | 0 | 0 |
| Unknown | 0 | 2 (22) | 2 (9) |
| **Treatment received after baseline OCT, \( n (\%) \)** | | | |
| None | 0 | 5 (56) | 5 (23) |
| Ablation only | 6 (46) | 1 (11) | 7 (32) |
| Ablation + anti-VEGF | 5 (38) | 2 (22) | 7 (32) |
| Surgery only | 1 (8) | 1 (11) | 2 (9) |
| Surgery + anti-VEGF | 1 (8) | 0 | 1 (5) |
| **Number of total OCTs per eye, mean ± SD (median, range)** | \( 7 ± 6 (6, 2–25) \) | \( 6 ± 5 (4, 3–17) \) | \( 7 ± 5 (5, 2–23) \) |
| **Duration of follow-up per eye, mo, mean ± SD (median, range)** | \( 26 ± 23 (13, 7–81) \) | \( 38 ± 22 (46, 5–73) \) | \( 31 ± 23 (23, 5–81) \) |

For eyes with follow-up ≥ 6 months, VA at baseline and change in VA from baseline to final follow-up were available for 13 treatment-naïve eyes and 7 previously treated eyes (2 previously treated eyes did not have VA at baseline but had documented VA at the final follow-up and were included in the study). VEGF, vascular endothelial growth factor.

*VA at baseline.
†VA from baseline to final follow-up.
‡Shields JA, Shields CL, Honavar SG, Demirci H, Cater J. Classification and management of Coats disease: the 2000 Proctor Lecture. *Am J Ophthalmol*. 2001;131:572–583.
TABLE 3. Association Between Central Subfield Spectral-Domain Optical Coherence Tomography Findings With Visual Acuity (VA) for Treatment-Naïve and Previously Treated Eyes at the Baseline Visit

| Presence of SD-OCT Finding at the Baseline Visit | Treatment-Naïve Eyes, n = 21 | Previously Treated Eyes, n = 16 | P Value |
|-------------------------------------------------|-----------------------------|-------------------------------|---------|
| VA at Baseline, Mean ± SD, logMAR                | VA at Baseline, Mean ± SD, logMAR | P Value |
| Presence of SD-OCT Finding at the Baseline Visit | n | VA at Baseline, Mean ± SD, logMAR | n | VA at Baseline, Mean ± SD, logMAR | P Value |
| VMA/VMT                                         | 0 | 0.87 ± 0.71 | - | 0 | 1.01 ± 0.88 | - |
| ERM                                             | 2 | 0.82 ± 0.62 | 0.76 | 6 | 0.93 ± 0.23 | 10.96 ± 1.12 | 0.51 |
| ERM deforming CSF                                | 1 | 0.89 ± 0.69 | 0.25 | 3 | 0.90 ± 0.35 | 13.96 ± 0.97 | 0.84 |
| Hyporeflective intraretinal cystoid spaces       | 8 | 0.72 ± 0.85 | 0.09 | 7 | 1.06 ± 0.59 | 9 | 0.87 ± 1.08 | 0.29 |
| SRF                                             | 4 | 1.80 ± 0.63 | 0.63 ± 0.50 | 0.008† | 0 | 0.95 ± 0.88 | 16 | 0.95 ± 0.88 | - |
| Any hyperreflective material                     | 13 | 0.26 ± 0.35 | 0.12 | 7 | 1.23 ± 1.02 | 7 | 0.49 ± 0.44 | 0.47 |
| Bright hyperreflectivities                       | 10 | 0.52 ± 0.55 | 0.01* | 10 | 0.50 ± 0.70 | 12 | 0.78 ± 0.64 | 0.02* |
| Intraretinal                                     | 10 | 0.52 ± 0.55 | 0.02* | 3 | 0.50 ± 0.70 | 12 | 0.78 ± 0.64 | 0.02* |
| Subretinal                                       | 7 | 0.56 ± 0.51 | 0.01* | 3 | 0.50 ± 0.70 | 12 | 0.78 ± 0.64 | 0.02* |
| Compact hyperreflective structure                | 5 | 0.76 ± 0.75 | 0.12 | 6 | 1.60 ± 0.88 | 10 | 0.56 ± 0.64 | 0.02* |
| With atrophy of overlying outer retina           | 5 | 0.76 ± 0.75 | 0.12 | 6 | 1.60 ± 0.88 | 10 | 0.56 ± 0.64 | 0.02* |
| Outer retinal atrophy                            | 5 | 0.20 ± 0.30 | 0.005† | 10 | 1.34 ± 0.86 | 6 | 0.30 ± 0.44 | 0.01* |
| Involving OPL/ONL                                | 4 | 0.70 ± 0.72 | 0.24 | 8 | 1.53 ± 0.84 | 8 | 0.38 ± 0.45 | 0.01* |
| Involving EZ/IZ                                   | 5 | 0.20 ± 0.30 | 0.005† | 10 | 1.34 ± 0.86 | 6 | 0.30 ± 0.44 | 0.01* |
| Involving RPE                                    | 4 | 0.30 ± 0.45 | 0.02* | 7 | 1.62 ± 0.86 | 6 | 0.43 ± 0.46 | 0.01* |

All 21 treatment-naïve eyes had VA at baseline while 16 of 18 previously treated eyes had VA at baseline. VMA, vitreomacular adhesion; VMT, vitreomacular traction; ERM, epiretinal membrane; OPL, outer plexiform layer; ONL, outer nuclear layer; EZ, ellipsoid zone; IZ, interdigitation zone; RPE, retinal pigment epithelium.

* Significant difference between or among groups, P < 0.05.
† Significant difference between or among groups, P < 0.01.
‡ Not above compact hyperreflective structure.
0.001), CSF thickness (P = 0.045), and total macular volume (P = 0.03). In contrast, change in VA was not correlated with change in foveal neurosensory thickness (P = 0.38) or foveal choroidal thickness (P = 0.77). Specifically, a decrease in foveal subretinal thickness, which has the strongest correlation with VA improvement, was found to be associated with baseline SRF present (n = 2): –329 ± 182 μm versus absent (n = 18): –8 μm ± 39 μm; P = 0.02) and baseline subretinal bright hyperreflectivities [present (n = 3): –183 ± 238 μm versus absent (n = 16): –16 μm ± 62 μm; P = 0.03].

**DISCUSSION**

This is the first study in the literature to show an association between both qualitative and quantitative SD-OCT features in the macula with VA in Coats’ disease. This study also included the largest number of children with Coats’ disease and these comprehensively examined OCT findings (n = 28) to date. A literature search on PubMed using the terms “optical coherence tomography”, “Coats’ disease”, “vision”, and “visual acuity” between January 1, 2007 and December 13, 2017 revealed no similar previously published manuscripts. Some prior studies have incorporated OCT imaging in the assessment of visual outcomes in subfoveal nodule/macular fibrosis, but did not include the comprehensive list of qualitative and quantitative findings as in our study. In our report, a compact hyperreflective structure (fibrotic nodule or macular fibrosis) and ORA were associated with worse VA at baseline for previously treated eyes, did not resolve after therapy, and were not associated with VA improvement post treatment. They were also more commonly present at the baseline and final visits in eyes with poor final VA (<20/200) when compared to eyes with good final VA (>20/60).
contrast, although bright hyperreflectivities (exudates), SRF, and foveal subretinal thickness were associated with poorer VA at baseline prior to the initiation of any treatment, they could resolve and were linked to an improvement in VA after therapy.

A compact hyperreflective structure (fibrotic nodule or macular fibrosis) in the CSF was associated with worse VA at baseline for previously treated eyes in this study. It also persisted despite therapy, did not progress to improvement in VA after therapy.

### TABLE 4. Association Between Central Subfield Spectral-Domain Optical Coherence Tomography Features With Visual Acuity for All Imaging Sessions for All Eyes (n = 144)

| Presence of SD-OCT Finding Across All Visits | Yes | No |
|---------------------------------------------|-----|----|
| VA at Corresponding Visit, Mean ± SD, logMAR |  |  |
| **Presence of SD-OCT Finding** | **Yes** | **No** | **P Value** |
| VMA/VMT | 11 | 132 | 0.30 |
| ERM | 30 | 114 | 0.24 |
| ERM deforming CSF | 8 | 134 | 0.34 |
| Hyporeflective intraretinal cystoid spaces | 64 | 80 | 0.06 |
| SRF | 6 | 138 | 0.10 |
| Any hyperreflective material | 75 | 67 | 0.01* |
| Bright hyperreflectivities | 39 | 103 | 0.27 |
| Intraretinal | 39 | 103 | 0.27 |
| Subretinal | 18 | 124 | 0.14 |
| Compact hyperreflective structure | 41 | 103 | 0.002† |
| With atrophy of overlying outer retina | 36 | 103 | 0.004† |
| Outer retinal atrophy§ | 99 | 32 | <0.001‡ |
| Involving OPL/ONL | 76 | 64 | <0.001‡ |
| Involving EZ/IZ | 84 | 44 | <0.001‡ |
| Involving RPE | 53 | 83 | 0.003† |

The generalized estimating equation was used given this analysis included longitudinal observations from the same patients. Except for 24 visits, all visits were after at least one treatment session for Coats’ disease. VMA, vitreomacular adhesion; VMT, vitreomacular traction; ERM, epiretinal membrane; OPL, outer plexiform layer; ONL, outer nuclear layer; EZ, ellipsoid zone; IZ, interdigitation zone; RPE, retinal pigment epithelium.

* Significant difference between or among groups, P < 0.05.
† Significant difference between or among groups, P < 0.01.
‡ Significant difference between or among groups, P < 0.001.
§ Not above compact hyperreflective structure.

A compact hyperreflective structure (fibrotic nodule or macular fibrosis) in the CSF was associated with worse VA at baseline for previously treated eyes in this study. It also persisted despite therapy, did not progress to improvement in.

### TABLE 5. Comparison Between Central Subfield Spectral-Domain Optical Coherence Tomography Findings at the Final Visit With Visual Acuity (VA) at the Final Visit For All Eyes With Follow-Up OCTs (n = 22)

| Presence of SD-OCT Findings at the Final Visit | Final VA > 20/60, n Affected/n Total (%) | Final VA < 20/200, n Affected/n Total (%) | P Value |
|-----------------------------------------------|------------------------------------------|------------------------------------------|---------|
| VMA/VMT | 0/11 | 0/6 | - |
| ERM | 1/11 (9) | 2/6 (33) | 0.51 |
| ERM deforming CSF | 1/11 (9) | 0/6 | 1.00 |
| Hyporeflective intraretinal cystoid spaces | 1/11 (9) | 4/6 (67) | 0.03* |
| SRF | 0/11 | 0/6 | - |
| Any hyperreflective material | 1/11 (9) | 4/5 (80) | 0.01* |
| Bright hyperreflectivities | 1/11 (9) | 0/5 | 1.00 |
| Intraretinal | 1/11 (9) | 0/5 | 1.00 |
| Subretinal | 0/11 | 0/5 | - |
| Compact hyperreflective structure | 0/11 | 4/6 (67) | 0.006† |
| With atrophy of overlying outer retina | 0/11 | 3/5 (60) | 0.02* |
| Outer retinal atrophy‡ | 5/11 (45) | 6/6 (100) | 0.04* |
| Involving OPL/ONL | 2/11 (18) | 6/6 (100) | 0.002† |
| Involving EZ/IZ | 5/11 (46) | 6/6 (100) | 0.04* |
| Involving RPE | 2/11 (18) | 6/6 (100) | 0.002† |

Five eyes had vision between 20/60 and 20/200. Number of total eyes was fewer than 11 for the VA >20/60 group and 6 for the VA <20/200 group for some of the SD-OCT features due to the inability to grade these features in some eyes. VMA, vitreomacular adhesion; VMT, vitreomacular traction; ERM, epiretinal membrane; OPL, outer plexiform layer; ONL, outer nuclear layer; EZ, ellipsoid zone; IZ, interdigitation zone; RPE, retinal pigment epithelium.

* Significant difference between or among groups, P < 0.05.
† Significant difference between or among groups, P < 0.01.
‡ Not above compact hyperreflective structure.
TABLE 6. Comparison Between Central Subfield Spectral-Domain Optical Coherence Tomography Findings at the Baseline Visit With Visual Acuity (VA) at the Final Visit for All Eyes With Follow-Up OCTs

| Presence of SD-OCT Findings at the Baseline Visit | Final VA > 20/60, n Affected/n Total (%) | Final VA < 20/200, n Affected/n Total (%) | P Value |
|--------------------------------------------------|------------------------------------------|------------------------------------------|---------|
| VMA/VMT                                          | 0/11 (0)                                 | 0/6 (0)                                  | -       |
| ERM                                              | 1/11 (9)                                 | 2/6 (33)                                 | 0.51    |
| ERM deforming CSF                                | 1/11 (9)                                 | 0/6 (0)                                  | 1.00    |
| Hyporeflective intraretinal cystoid spaces       | 5/11 (27)                                | 4/6 (67)                                 | 0.16    |
| SRF                                              | 2/11 (18)                                | 1/6 (17)                                 | 0.51    |
| Any hyperreflective material                     | 5/11 (45)                                | 4/5 (80)                                 | 0.59    |
| Bright hyperreflectivities                       | 5/11 (45)                                | 1/5 (20)                                 | 0.59    |
| Intraretinal                                     | 5/11 (45)                                | 1/5 (20)                                 | 0.59    |
| Subretinal                                       | 2/11 (18)                                | 1/5 (20)                                 | 1.00    |
| Compact hyperreflective structure                | 0/11 (0)                                 | 3/6 (50)                                 | 0.03*   |
| With atrophy of overlying outer retina           | 0/11 (0)                                 | 2/5 (40)                                 | 0.08    |
| Outer retinal atrophy‡                           | 2/8 (25)                                 | 5/5 (100)                                | 0.02*   |
| Involving OPL/ONL                                | 1/10 (10)                                | 5/5 (100)                                | 0.002†  |
| Involving EZ/IZ                                   | 2/8 (25)                                 | 5/5 (100)                                | 0.02*   |
| Involving RPE                                    | 1/9 (11)                                 | 4/5 (80)                                 | 0.02*   |

Twenty-two eyes had VA at the most recent follow-up. Five eyes had VA between 20/60 and 20/200. Number of total eyes was fewer than 11 for the VA >20/60 group and 6 for the VA <20/200 group for some of the SD-OCT features due to the inability to grade these features in some eyes. VMA, vitreomacular adhesion; VMT, vitreomacular traction; ERM, epiretinal membrane; OPL, outer plexiform layer; ONL, outer nuclear layer; EZ, ellipsoid zone; IZ, interdigitation zone; RPE, retinal pigment epithelium.

* Significant difference between or among groups, P < 0.05.
† Significant difference between or among groups, P < 0.01.
‡ Not above compact hyperreflective structure.
VA, and was associated with poorer VA after treatment for all eyes with follow-up. Subfoveal nodule or macular fibrosis in Coats’ disease has been shown to be associated with poor visual outcomes in prior publications.\textsuperscript{10–13,15} While Daruich et al.\textsuperscript{16} made a distinction between subfoveal nodule (defined as a yellow exudative, protruding, spheroidal lesion) and macular fibrosis (defined as a subretinal white-gray scar at the fovea), Jumper et al.\textsuperscript{13} and Shields et al.\textsuperscript{15} used the two terms interchangeably. We did not make a distinction between the two terms since it is still unknown if they (Figs. 1G, 1H, 2, 3C, 3D) are indeed two distinct entities or part of a spectrum of disease findings. Fibrosis has been postulated to cause decreased vision by disrupting the highly organized tissue architecture in the retina.\textsuperscript{22} Our study is the first to also report local destruction of the photoreceptors and retinal pigment epithelium overlying the compact hyperreflective structure in Coats’ disease. This localized ORA likely also contributes to visual loss in these eyes.

Next, ORA (not above a compact hyperreflective structure) was associated with poor VA at baseline in both treatment-naïve and previously treated eyes, did not resolve with therapy, and was more commonly found at baseline and the most recent follow-up in eyes with poor (<20/200) final VA. ORA has been associated with poor VA in many other ocular conditions.\textsuperscript{22,23} but our study is the first to identify photoreceptor and retinal pigment epithelium atrophy at baseline as a macular feature associated with poor VA at follow-up in Coats’ disease. Mechanistically, ORA in Coats’ disease may develop secondary to chronic exudation and fluid, as well as from underlying fibrosis or ischemic or inflammatory effects.

Meanwhile, baseline SRF in the CSF was associated with poor VA prior to any treatment but this finding resolved after treatment with resultant improvement in foveal subretinal thickness and VA. Consequently, neither SRF at baseline or the final visit was associated with poor VA at the final visit. In contrast to our study findings, without using OCT, Shields and colleagues\textsuperscript{15} found that subfoveal fluid at the final follow-up was the reason for final VA worse than 20/200 in 47% of 79 eyes, while Al-Qahtani and colleagues\textsuperscript{24} reported that the only baseline structural change that was associated with poor visual outcomes, after adjusting for potential confounders and by using multivariate analyses, was SRF in all four quadrants with foveal involvement. We suspect the difference between these studies and our present report to be due to a difference in study population, as patients with retinal detachments in all four quadrants are likely to have higher macular detachment and are not likely to be imaged with OCT, as in our study that did not have any stage 3B treatment-naïve eyes. Differences in outcomes may also be impacted by frequency or selection of treatments to achieve anatomic resolution of disease.\textsuperscript{3}

Both intraretinal and subretinal bright hyperreflectivities (exudates) in the CSF at baseline were also associated with poor VA prior to any treatment, but these baseline exudates could resolve after treatment. Specifically, baseline intraretinal bright hyperreflectivities (exudates) were associated with an improvement in VA from baseline to the final visit. Eyes with baseline subretinal bright hyperreflectivities (exudates) also demonstrated a greater improvement in VA compared to those without, but this relationship did not reach statistical significance. Given the small number of subjects in this study, this finding should be interpreted with caution since the small sample size may have limited the ability to detect differences across groups.

We also specifically examined two eyes with advanced disease and dense SRF and exudation at presentation, and demonstrated that SRF and exudates resolved after treatment but that fibrosis and ORA can subsequently form (Fig. 4). The eye that developed fibrosis and ORA affecting the fovea had
FIGURE 5. Correlation between change in retinal thickness measurements (at the foveal center, across the central subfield and macula) and change in VA from baseline to the most recent follow-up. Decreases in foveal total retinal thickness, foveal subretinal thickness, central subfield thickness, and total macular volume were positively correlated with improvements in VA (−logMAR) while there was no correlation between change in foveal neurosensory retinal thickness or foveal choroidal thickness with change in VA.
Table 7. Association Between Central Subfield Spectral-Domain Optical Coherence Tomography Findings at the Baseline Visit With Change in Visual Acuity (VA) From Baseline to Final Visit in All Eyes With Follow-Up

| Presence of SD-OCT Finding at the Baseline Visit | Change in VA From Baseline to The Final Visit, Mean ± SD, logMAR | Change in VA From Baseline to The Final Visit, Mean ± SD, logMAR | P Value |
|-------------------------------------------------|---------------------------------------------------------------|---------------------------------------------------------------|---------|
| VMA/VMT                                         |                                                               |                                                               |         |
| ERM                                             |                                                               |                                                               |         |
| ERM deformating CSF                             |                                                               |                                                               |         |
| Hyporeflective intraretinal cystoid spaces       |                                                               |                                                               |         |
| SRF                                             |                                                               |                                                               |         |
| Any hyperreflective material                    |                                                               |                                                               |         |
| Bright hyperreflectivities                      |                                                               |                                                               |         |
| Involving EZ/IZ                                  |                                                               |                                                               |         |
| Subretinal                                       |                                                               |                                                               |         |
| Compact hyperreflective structure               |                                                               |                                                               |         |
| With atrophy of overlying outer retina          |                                                               |                                                               |         |
| Outer retinal atrophy†                          |                                                               |                                                               |         |
| Involving OPL/ONL                               |                                                               |                                                               |         |
| Involving EZ/IZ                                  |                                                               |                                                               |         |
| Involving RPE                                    |                                                               |                                                               |         |

Twenty eyes had VA documented at both baseline and most recent follow-up and were included in this analysis. VMA, vitreomacular adhesion; VMT, vitreomacular traction; ERM, epiretinal membrane; OPL, outer plexiform layer; ONL, outer nuclear layer; EZ, ellipsoid zone; IZ, interdigitation zone; RPE, retinal pigment epithelium.

† Significant difference between or among groups, P < 0.05.

In conclusion, SD-OCT is an essential component of multimodal imaging in the diagnosis and prognosis of Coats’ disease in eyes in which macular imaging is possible. This study demonstrated that fibrotic nodules/macular fibrosis and ORA persisted after treatment and their presence at baseline and final visit were therefore associated with poor VA at the most recent follow-up. Meanwhile, untreated SRF, retinal exudation, and foveal subretinal thickness caused poor VA at baseline but these features could improve after treatment with good VA outcomes. Determination of these SD-OCT findings at the initial visit can help providers prognosticate visual outcomes and decide treatment strategies accordingly, and highlight the importance of incorporating multimodal imaging in this disease. Although these SD-OCT findings are promising prognostic imaging biomarkers, it will be important to properly validate these biomarkers in future studies before they can be reliably used in clinical research and clinical practice.

Acknowledgments

Presented at the annual meeting of the Association for Research in Vision and Ophthalmology, Honolulu, Hawaii, United States, April 29–May 3, 2018.

The authors thank Katrina P. Winter, BS, Du Tran-Viet, BS, and Vincent Tai, MS, for assistance with image acquisition and analysis. Supported by The International Retinal Research Foundation, The Hartwell Foundation, The Andrew Family Charitable Foundation, National Institutes of Health (NIH) Grants 1RO1 EY025009 and U11 RR024128 (Pilot project grant) from Duke Translational Research Institute and NIH Roadmap for Medical Research. The writing and content of the paper are solely the responsibility of the authors and do not necessarily represent the official view of NIH. The sponsors or funding organizations had no role in the design or conduct of this research.
References

1. Shields J, Shields C. Review: coats disease, the 2001 LuEsther T. Mertz lecture. Retina. 2001;21:80–91.
2. Rubin MP, Mukai S. Coats’ disease. Int Ophthalmol Clin. 2008;48:149–158.
3. Ong SS, Buckley EG, McCuen BW II, et al. Comparison of visual outcomes in coats’ disease: a 20-year experience. Ophthalmology. 2017;124:1368–1376.
4. Suzani M, Moore AT. Intraoperative fluorescein angiography-guided treatment in children with early Coats’ disease. Ophthalmology. 2015;122:1195–1202.
5. Shields CL, Mashayekhi A, Luo CK, Materin MA, Shields JA. Optical coherence tomography in children: analysis of 44 eyes with intraocular tumors and simulating conditions. J Pediatr Ophthalmol Strabismus. 2004;41:338–344.
6. Henry CR, Berrocal AM, Hess DJ, Murray TG. Intraoperative spectral-domain optical coherence tomography in Coats’ patients. Ophthalbimic Surg Lasers Imaging Retina. 2012;43: e80–e84.
7. Kessner R, Barak A, Neudorfer M. Intraretinal exudates in Coats’ disease as demonstrated by spectral-domain OCT. Case Rep Ophthalbimol. 2012;3:11–15.
8. Hautz W, Golebiewska J, Kocyla-Karczmarewicz B. Optical coherence tomography and optical coherence tomography angiography in monitoring Coats’ disease. J Ophthalbimol. 2017;2017:7849243.
9. Muakkassa NW, de Carlo TE, Choudhry N, Duker JS, Baumal CR. Optical coherence tomography angiography findings in Coats’ disease. Ophthalbimic Surg Lasers Imaging Retina. 2016;47:632–635.
10. Daruich AL, Moulin AL, Tran HV, Matet A, Munier FL. Subfoveal nodule in Coats’ disease: toward an updated classification predicting visual prognosis. Retina. 2017;37:1591–1598.
11. Sigler EJ, Calzada JJ. Retinal angiomatous proliferation with chorioretinal anastomosis in childhood Coats disease: a reappraisal of macular fibrosis using multimodal imaging. Retina. 2015;35:557–546.
12. Rabioso A, Marchese A, Sacconi R, et al. Refining Coats’ disease by ultra-widefield imaging and optical coherence tomography angiography. Graefes Arch Clin Exp Ophthalbimol. 2017;255:1881–1890.
13. Jumper JM, Pomerleau D, McDonald HR, Johnson RN, Fu AD, Cunningham ET Jr. Macular fibrosis in Coats disease. Retina. 2010;30(4 suppl):S9–S14.
14. The IONDT Research Group. The ischemic optic neuropathy decompression trial (IONDT): design and methods. Control Clin Trials. 1998;19:276–296.
15. Shields JA, Shields CL, Honavar SG, Demirci H, Cater J. Classification and management of Coats disease: the 2000 Proctor Lecture. Am J Ophthalbimol. 2001;131:572–583.
16. Maldonado RS, Izatt JA, Sarin N, et al. Optimizing hand-held spectral domain optical coherence tomography imaging for neonates, infants, and children. Invest Ophthalbimol Vis Sci. 2010;51:2678–2685.
17. Folgar FA, Yuan EL, Farsiu S, Toth CA. Lateral and axial measurement differences between spectral-domain optical coherence tomography systems. J Biomed Opt. 2014;19:16014.
18. Folgar FA, Yuan EL, Farsiu S, Toth CA. Errata: Lateral and axial measurement differences between spectral-domain optical coherence tomography systems. J Biomed Opt. 2015;20:59802.
19. Otani T, Yamaguchi Y, Kishi S. Serous macular detachment secondary to distant retinal vascular disorders. Retina. 2004;24:758–762.
20. Zeger SL, Liang KY, Albert PS. Models for longitudinal data: a generalized estimating equation approach. Biometrics. 1988;44:1049–1060.
21. Friedlander M. Fibrosis and diseases of the eye. J Clin Invest. 2007;117:576–586.
22. Bhisitkul RB, Mendes TS, Rofigha S, et al. Macular atrophy progression and 7-year vision outcomes in subjects from the ANCHOR, MARINA, and HORIZON studies: the SEVEN-UP study. Am J Ophthalbimol. 2015;159:915–924, e912.
23. Santos AR, Costa MA, Schwartz C, et al. Optical coherence tomography baseline predictors for initial best-corrected visual acuity response to intravitreal anti-vascular endothelial growth factor treatment in eyes with diabetic macular edema: the Chartres Study. Retina. 2018;38:1110–1119.
24. Al-Qahtani AA, Almasaud JM, Ghazi NG. Clinical characteristics and treatment outcomes of coats disease in a Saudi Arabian population. Retina. 2015;35:2091–2099.